Wonbiogen Co.,Ltd.
KOSDAQ
₩5,850.00
-2.99%
Delayed · cached 15 min
Fair value analysis
307280
Wonbiogen Co.,Ltd.
₩5,850.00
Close used for this calculation
₩14,289.56Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
77/100
Quality radar
Consensus fair value
₩14,289.56
Below FV▲ +144.3% against the close used
Model range ₩1,663.30 – ₩18,660.00
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₩1,663.30Fair value₩14,289.56Bull₩18,660.00
FairClose
52-week traded range
52W low ₩4,875.0052W high ₩8,250.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading below the consensus fair value
Wonbiogen Co.,Ltd. closed at ₩5,850.00, 59.1% below the consensus fair value of ₩14,289.56 drawn from 8 valuation models.
Financial DNA score 77/100 — Strong. P/E of 6.3x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₩17,628.73
+201.3%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₩11,310.31
+93.3%
√(22.5 × EPS × BVPS)
EPS=933, BVPS=6093.75
P/E Fair Value
₩18,660.00
+219.0%
EPS × 20x (sector P/E)
EPS=933, Sector P/E=20x
EV/EBITDA
₩11,396.48
+94.8%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=7.93B
Dividend Discount (DDM)
₩1,663.30
-71.6%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=130.46, r=10%, g=2%
Book Value (P/B)
₩10,864.29
+85.7%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=6093.75, ROE=15.5%, g=3%, r=10%
Reverse DCF
₩5,850.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: -9% | Historical: 0%
Margin of Safety
₩11,899.76
+103.4%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=15866.35, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.